StocksMedium•6 November 2026•
1 min read
Novavax Shares Slide 8% Despite Q3 Earnings Beat and Improved 2026 Revenue Outlook
Key Facts
1Novavax shares fell 8% despite the company beating Q3 earnings and revenue estimates.
2The company raised its 2026 revenue guidance to $400 million, driven by milestone payments from Sanofi.
Novavax shares fell 8% despite the company beating Q3 earnings and revenue estimates. Zacks reported that the company raised its 2026 revenue guidance to $400 million, driven by milestone payments from Sanofi.
Novavax closed at $9.78 on November 5, 2026, after trading between a low of $9.39 and a high of $10.68. During the same period, Sanofi closed at $46.91 on November 5, 2026, as Novavax benefited from a $125 million milestone payment from the partner company.